

Press release

EQ_L PHARMA

Lund, April 7th, 2021

EQ_L Pharma AB (publ)

556713-3425

EQ_L becomes Nordic representative for Qilu Pharmaceuticals

Qilu Pharmaceuticals (Qilu) has today received approval for Gefitinib Qilu tablet 250mg in Norway and the product is expected to be approved in Denmark and Sweden soon. Gefitinib Qilu is the first of currently seven pharmaceuticals in which EQ_L will act as a local representative for Qilu in the Nordic region. As a local representative, EQ_L buys, stocks and sells pharmaceuticals for Qilu in the Nordic region. Registration of the pharmaceuticals, on the other hand, is done by Qilu and they own all rights and have all obligations a registration brings with it from the Authorities.

Qilu Pharmaceuticals is a leading Chinese pharmaceutical company with eight production facilities, more than 15,000 employees and over 200 products in its range.

Gefitinib Qilu is a so-called protein kinase inhibitor which is used in the treatment of non-small cell lung cancer. The total market in Sweden, Denmark and Norway amounts to approximately SEK 10 million with five active competitors. In Sweden, Gefitinib is an outpatient drug, while in Denmark and Norway it is sold in inpatient care via public procurement. Gefitinib Qilu is expected to be launched in EQ_L's third financial quarter of 2021/22.

In practice, Gefitinib Qilu will be included in EQ_L Pharma's portfolio like any other product and the Qilu products' sales and profits will not be reported separately in future financial reports.

For further information, please contact:

Christer Fåhraeus

CEO, EQ_L Pharma AB (publ)

Phone: +46 (0) 705 – 60 90 00

E-mail: christer.fahraeus@eqlpharma.com

Website: www.eqlpharma.com

Eq_L Pharma AB (Publ) briefly

EQ_L Pharma AB specializes in developing and selling generics, ie pharmaceuticals that are medically equivalent to reference pharmaceuticals. The company currently has upwards of 20 niche generics (ie generics with limited competition apart from the reference pharmaceutical) approved in the Nordic markets. In addition to these, there is a significant pipeline of additional niche generics for launch in 2021 and beyond. The business is currently entirely focused on prescription pharmaceuticals, including hospital products, in the Nordic region and in selected European markets. EQ_L Pharma AB conducts its operations in Lund and is listed on the Spotlight Stock Market. EQ_L Pharma AB conducts extensive development work in collaboration with leading contract manufacturers and pharmaceutical companies in the EU and Asia, among others.